Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds
Open Access
- 6 July 2006
- journal article
- Published by BMJ in Journal of Medical Genetics
- Vol. 44 (1) , 44-50
- https://doi.org/10.1136/jmg.2006.045153
Abstract
The major determinant of age of onset in Huntington's disease is the length of the causative triplet CAG repeat. Significant variance remains, however, in residual age of onset even after repeat length is factored out. Many genetic polymorphisms have previously shown evidence of association with age of onset of Huntington's disease in several different populations. To replicate these genetic association tests in 443 affected people from a large set of kindreds from Venezuela. Previously tested polymorphisms were analysed in the HD gene itself (HD), the GluR6 kainate glutamate receptor (GRIK2), apolipoprotein E (APOE), the transcriptional coactivator CA150 (TCERG1), the ubiquitin carboxy-terminal hydrolase L1 (UCHL1), p53 (TP53), caspase-activated DNase (DFFB), and the NR2A and NR2B glutamate receptor subunits (GRIN2A, GRIN2B). The GRIN2A single-nucleotide polymorphism explains a small but considerable amount of additional variance in residual age of onset in our sample. The TCERG1 microsatellite shows a trend towards association but does not reach statistical significance, perhaps because of the uninformative nature of the polymorphism caused by extreme allele frequencies. We did not replicate the genetic association of any of the other genes. GRIN2A and TCERG1 may show true association with residual age of onset for Huntington's disease. The most surprising negative result is for the GRIK2 (TAA)(n) polymorphism, which has previously shown association with age of onset in four independent populations with Huntington's disease. The lack of association in the Venezuelan kindreds may be due to the extremely low frequency of the key (TAA)(16) allele in this population.Keywords
This publication has 38 references indexed in Scilit:
- Modulation of age at onset of Huntington disease patients by variations in TP53 and human caspase activated DNase (hCAD) genesNeuroscience Letters, 2005
- Apolipoprotein E genotypes do not influence the age of onset in Huntington's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2004
- NR2A and NR2B receptor gene variations modify age at onset in Huntington diseaseneurogenetics, 2004
- DNA Haplotype Analysis of CAG Repeat in Taiwanese Huntington’s Disease PatientsEuropean Neurology, 2004
- Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16neurogenetics, 2004
- The gender effect in juvenile Huntington disease patients of Italian originAmerican Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2003
- A Genome Scan for Modifiers of Age at Onset in Huntington Disease: The HD MAPS StudyAmerican Journal of Human Genetics, 2003
- Recent advances in Huntingtonʼs disease: implications for experimental therapeuticsCurrent Opinion in Neurology, 2002
- Analysis of CAG and CCG repeats in Huntingtin gene among HD patients and normal populations of IndiaEuropean Journal of Human Genetics, 2000
- Apolipoprotein E in the genetics and epidemiology of Alzheimer's diseaseAmerican Journal of Medical Genetics, 1995